

Supporting Information for


Oxidative [3+2]-annulation of nitroalkenes and azolium ylides in the presence of Cu(II): efficient synthesis of [5,5]-annulated *N*-fused heterocycles

Vladimir Motornov,^a Andrey A. Tabolin,^a Sema L. Ioffe^a

^a N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Leninsky prosp. 47, Moscow, 119991, Russia.


General experimental.

All reactions were performed in oven-dried (150 °C) glassware. Most of the chemicals were acquired from commercial sources and used as received. Starting nitroalkenes were prepared by literature procedures: **1a**,^{s1} **1b**,^{s2} **1c-1d**,^{s1} **1e-1f**,^{s3} **1g**,^{s4} **1h-1i**,^{s5} **1j**,^{s6} **1k**,^{s4} **1l**.^{s7} Other starting materials were prepared according to the literature procedures: **2a**,^{s3} **2f**.^{s4} TLC were performed on silica coated on aluminium with UV254 indicator. Visualization was accomplished with UV. Column chromatography was performed on silica (0.04–0.063 mm, 60 Å). NMR spectra were recorded at the 300 MHz (¹H NMR), 75 MHz (¹³C NMR), and 282 MHz (¹⁹F NMR) frequencies. Multiplicities are assigned as s (singlet), d (doublet), t (triplet), q (quadruplet), m (multiplet), br (broad). High resolution mass spectra were acquired at TOF spectrometer using electrospray ionization (ESI). Positions of pyrrolo[2,1-b]thiazole and pyrrolo[1,2-b]indazole rings are numerated according to IUPAC as shown. Assignment was made on the basis of 2D NMR (COSY, HSQC, HMBC) for compounds **3c**, **5a**, **5b**, **5e**, **5f**, **7f**.



For the salts **2** and **6** intensities of CH₂-group signals can be reduced due to their high acidity that causes proton exchange with water in DMSO-d₆. More significant decrease of CH₂-group intensity is attributed to higher acidity (e.g. for compound **2c**).

List of starting reagents:



1a, R¹ = F, R² = 4-Cl-C₆H₄-

1b, R¹ = F, R² = 2-Cl-C₆H₄-

1c, R¹ = F, R² = 4-MeO-C₆H₄-

1d, R¹ = F, R² = 4-NO₂-C₆H₄-

1e, R¹ = CO₂Et, R² = 4-Cl-C₆H₄-



1f, R¹ = CO₂Et, R² = 2-Br-C₆H₄-

1g, R¹ = H, R² = 4-Cl-C₆H₄-

1h, R¹ = H, R² = Ph

1i, R¹ = H, R² = 4-MeO-C₆H₄-

1j, R¹ = H, R² = 2-Br-C₆H₄-



Synthesis of thiazolium salts **2a-2c**:

To the solution of thiazole (255 mg, 3 mmol) in EtOAc (3 ml) corresponding bromoacetophenone (3 mmol) was added and the mixture was stirred at r.t. for 3 days. Precipitated product **2** was filtered, washed with EtOAc and dried under air.

3-(2-Oxo-2-phenylethyl)-1,3-thiazol-3-ium bromide 2a

White solid, yield 0.79 g (93%). mp = 232-235°C (dec.) (EtOAc) (lit. 223-223.5°C (dec.))^{s8}
NMR matches previously reported data.^{s9}

3-[2-(3-Methoxyphenyl)-2-oxoethyl]-1,3-thiazol-3-ium bromide 2b

White amorphous solid, yield 0.84 g (89%).

¹H NMR (300 MHz, DMSO-d₆): δ 3.83 (s, 3H, OMe), 6.45 (s, 2H, CH₂), 7.30-7.37 (m, 1H, CH_{Ar}), 7.48-7.66 (m, 3H, CH_{Ar}), 8.39 (s, *J* = 2.1 Hz, 1H, CH(thiazole)), 8.51 (d, *J* = 2.1 Hz, 1H, CH(thiazole)), 10.22 (s, 1H, H2(thiazole)).

¹³C NMR (75 MHz, DMSO-d₆, DEPT-135): δ 56.1 (OMe), 61.1 (CH₂), 113.3 (CH_{Ar}), 121.0 (CH_{Ar}), 121.1 (CH_{Ar}), 126.5 (CH(thiazole)), 130.9 (CH_{Ar}), 135.2 (C_{Ar}), 138.8 (CH(thiazole)), 160.0 (C_{Ar}-OMe), 161.9 (CH(thiazole)), 191.0 (C=O).

HRMS (ESI): *m/z* calcd. for [C₁₂H₁₂BrNO₂S - Br]⁺: 234.0583, found: 234.0586.

3-[2-(3-Nitrophenyl)-2-oxoethyl]-1,3-thiazol-3-ium bromide 2c

White solid, yield 0.90 g (91%). mp = 234-236°C (dec.) (EtOAc)

¹H NMR (300 MHz, DMSO-d₆): δ 6.48 (s, 2H, CH₂, proton exchange with water), 7.96 (app t, *J* = 8.1 Hz, 1H, CH_{Ar}), 8.40 (dd, *J* = 3.6, 2.5 Hz, 1H, CH_{Ar}), 8.44 (br s, 1H, CH(thiazole)), 8.46-8.50 (m, 2H, CH), 8.59 (dd, *J* = 8.1, 1.7 Hz, 1H, CH_{Ar}), 8.72 (app t, *J* = 1.7 Hz, 1H, CH_{Ar}), 10.18 (s, 1H, H2(thiazole)).

¹³C NMR (75 MHz, DMSO-d₆, DEPT-135): δ 123.0 (CH_{Ar}), 126.6 (CH(thiazole)), 129.1 (CH_{Ar}), 131.5 (CH_{Ar}), 134.8 (CH_{Ar}), 135.3 (C_{Ar}), 138.7 (CH(thiazole)), 148.5 (C_{Ar}-NO₂), 162.1 (CH(thiazole)), 190.0 (C=O).

HRMS (ESI): *m/z* calcd. for [C₁₁H₉BrN₂O₃S-Br]⁺: 249.0328, found: 249.0339

3-(2-Ethoxy-2-oxoethyl)-1,3-thiazol-3-ium bromide 2d

Solution of thiazole (425 mg, 5 mmol) and ethyl bromoacetate (835 mg, 5 mmol) in toluene (5 ml) was heated at 100°C for 36 hours, then cooled to r. t. Mother liquor was removed and the precipitated slightly yellow oil was triturated with PhMe and dried in vacuo to give 1.04 g (82%) of **2d** as a slightly yellow semisolid.

¹H NMR (300 MHz, DMSO-d₆): δ 1.21 (t, *J* = 7.1 Hz, 3H, CH₃), 4.19 (q, *J* = 7.1 Hz, 2H, OCH₂CH₃), 5.68 (s, 2H, N⁺-CH₂), 8.39 (m, 1H, CH(thiazole)), 8.58 (d, *J* = 3.4 Hz, 1H, CH(thiazole)), 10.32 (s, 1H, H2(thiazole)).

¹³C NMR (75 MHz, DMSO-d₆, DEPT-135): δ 14.4 (CH₃), 55.0 (N-CH₂), 62.3 (OCH₂CH₃), 126.8 (CH), 138.5 (CH), 162.1 (CH), 166.6 (CO₂Et).

HRMS (ESI): *m/z* calcd. for [C₇H₁₀BrNO₂S-Br]⁺: 172.0427, found: 172.0424

3-[2-(Benzyloxy)-2-oxoethyl]-1,3-thiazol-3-ium bromide 2e

Solution of thiazole (255 mg, 3 mmol) and benzyl bromoacetate (687 mg, 3 mmol) in EtOAc (3 ml) was refluxed for 24 hours, then cooled to r. t. Precipitated solid was filtered and dried under air to give 735 mg (78%) of **2e** as a white solid.

mp = 109-112°C (EtOAc)

¹H NMR (300 MHz, DMSO-d₆): δ 5.23 (s, 2H, O-CH₂), 5.74 (s, 2H, N⁺-CH₂), 7.30-7.42 (m, 5H, CH_{Ph}), 8.38 (s, *J* = 2.4 Hz, 1H, CH(thiazole)), 8.58 (d, *J* = 2.4 Hz, 1H, CH(thiazole)), 10.31 (s, 1H, H2(thiazole)).

¹³C NMR (75 MHz, DMSO-d₆, DEPT-135): δ 55.0 (N-CH₂), 67.9 (OCH₂Ph), 126.8 (CH(thiazole)), 128.7 128.9 (CH_{Ph}), 129.0 (CH_{Ph}), 135.4 (C_{Ph}), 138.6 (CH(thiazole)), 162.3 (CH(thiazole)), 166.6 (CO₂Et).

HRMS (ESI): *m/z* calcd. for [C₁₂H₁₂BrNO₂S-Br]⁺: 234.0583, found: 234.0577

3-(2-Oxopropyl)-1,3-thiazol-3-ium chloride 2f

Solution of thiazole (255 mg, 3 mmol) and chloroacetone (278 mg, 3 mmol) in toluene (3 ml) was heated at 100°C for 24 hours, then maintained at r. t. for 8 hours. Precipitated material was filtered, washed with PhMe and dried under air to give 325 mg (61%) of **2f** as a brown solid.

mp = 132-133°C (dec.) (PhMe)

¹H NMR (300 MHz, DMSO-d₆): δ 2.26 (s, 3H, Me), 5.80 (s, 2H, CH₂, proton exchange with water), 8.35 (br s, 1H, CH(thiazole)), 8.43 (br s, 1H, CH(thiazole)), 10.18 (s, 1H, H2(thiazole)).

¹³C NMR (75 MHz, DMSO-d₆, DEPT-135): δ 27.5 (CH₃), 62.9 (N⁺-CH₂), 126.4 (CH), 138.5 (CH), 161.5 (CH), 199.9 (C=O).

HRMS (ESI): *m/z* calcd. for [C₆H₈CINOS-Cl]⁺: 142.0321, found: 142.0331

Synthesis of indazolium salts **6a-6b**:

1-Methyl-2-(2-oxo-2-phenylethyl)-1H-indazol-2-ium bromide 6a

A solution of 1-methyl-1H-indazole (264 mg, 2 mmol) and 2-bromoacetophenone (398 mg, 2 mmol) in toluene (2 ml) was heated at 100°C for 2 days. The mixture was cooled down and the precipitated white solid **6a** (549 mg, 83%) was filtered, washed with toluene and dried under air.

mp = 189-192°C (EtOAc)

¹H NMR (300 MHz, DMSO-d₆): δ 4.27 (s, 3H, Me), 6.94 (s, 2H, CH₂, proton exchange with water), 7.57 (app t, *J* = 6.9 Hz, 1H, CH_{Ar}), 7.63-7.74 (m, 2H, CH_{Ar}), 7.82 (app t, *J* = 6.9 Hz, 1H, CH_{Ar}), 7.90-7.97 (m, 1H, CH_{Ar}), 8.05-8.23 (m, 4H, CH_{Ar}), 9.35 (s, 1H, H3(indazole)).

¹³C NMR (75 MHz, DMSO-d₆, DEPT-135): δ 34.1 (N-Me), 58.1 (CH₂), 111.9 (CH), 119.4 (C_q), 123.7 (CH), 125.7 (CH), 129.1 (CH), 129.6 (CH), 133.8 (C_q), 133.9 (CH), 134.8 (CH), 135.4 (CH), 140.8 (C_q), 191.1 (C=O).

HRMS (ESI): *m/z* calcd. for [C₁₆H₁₅N₂O]⁺: 251.1179, found: 251.1183

2-(2-Ethoxy-2-oxoethyl)-1-methyl-1H-indazol-2-ium bromide 6b

A solution of 1-methyl-1H-indazole (264 mg, 2 mmol) and ethyl bromoacetate (0.28 ml, 418 mg, 2.5 mmol) in toluene (2 ml) was heated at 100°C for 4 days. The mixture was cooled down and the precipitated white solid **6b** (281 mg, 47%) was filtered, washed with toluene and dried under air.

mp = 154-156°C (PhMe)

¹H NMR (300 MHz, DMSO-d₆): δ 1.27 (s, 3H, -CH₂-CH₃), 4.29 (br s, 5H, N-Me + OCH₂-), 6.04 (s, 2H, N⁺-CH₂), 7.56 (br s, 1H, CH_{Ar}), 7.89-7.97 (m, 1H, CH_{Ar}), 8.00-8.08 (m, 1H, CH_{Ar}), 8.18 (d, *J* = 7.7 Hz, 1H, CH_{Ar}), 9.36 (s, 1H, H3(indazole)).


^{13}C NMR (75 MHz, DMSO- d_6 , DEPT-135): δ 14.4 (-CH₂-CH₃), 34.1 (N-Me), 51.9 (N⁺-CH₂-), 63.1 (CH₂CH₃), 111.9 (CH), 119.3 (C_q), 123.8 (CH), 125.9 (CH), 134.3 (CH), 135.0 (CH), 140.9 (C_q), 165.9 (CO₂Et).

HRMS (ESI): m/z calcd. for [C₁₂H₁₅N₂O₂]⁺: 219.1128, found: 219.1125

General procedure 1 for the synthesis of 7-fluoropyrrolo[2,1-b]thiazoles 3.

To the solution of thiazolium salt **2** (0.5 mmol, 2.5 equiv.) in dry DMSO (1 ml) powdered 4Å molecular sieves (100 mg) and 2,6-lutidine (107 mg, 1 mmol, 5 equiv.) were added, followed by addition of nitroalkene **1** (0.2 mmol, 1.0 equiv.) and Cu(OCOCF₃)₂·H₂O (123 mg, 0.4 mmol, 2.0 equiv.) The mixture was stirred at r. t. for 1 h – 3 d. After the reaction was complete (TLC monitoring), it was quenched with EtOAc/1% aqueous Na₂EDTA solution (30/30 ml). Aqueous layer was extracted with 3*30 ml EtOAc. Combined organic layer was dried over anhydrous Na₂SO₄ and evaporated after addition of silica gel. Crude product was purified by column chromatography using PE/EtOAc as an eluent to give pyrrolo[2,1-b]thiazoles **3**.

[6-(4-Chlorophenyl)-7-fluoropyrrolo[2,1-b][1,3]thiazol-5-yl](phenyl)methanone 3a



Pyrrolo[2,1-b]thiazole **3a** was obtained from α -fluoronitroalkene **1a** (40.3 mg, 0.2 mmol) and thiazolium salt **2a** (2.5 equiv.) following the general procedure 1 (reaction time 5 h). Column chromatography (eluent: 15:1 PE/EtOAc) afforded **3a** (44 mg, 62%) as a yellow solid.

R_f = 0.36 (PE/EtOAc, 3:1) (UV) mp = 128-129°C (CHCl₃)


^1H NMR (300 MHz, CDCl₃): δ 6.94 (d, J = 4.2 Hz, 1H, H₂), 6.97-7.03 (m, 4H, CH_{Ar}), 7.06 (d, J = 7.8 Hz, 2H, CH_{Ar}), 7.24 (m, 1H, CH_{Ar}), 7.33 – 7.39 (m, 2H, CH_{Ar}), 8.78 (dd, J = 4.2, 1.9 Hz, 1H, H₃).

^{13}C NMR (75 MHz, CDCl₃): δ 113.1 (C₂-H), 117.2 (C₅), 122.8 (d, $^2J_{CF}$ = 9.1 Hz, C₆), 123.9 (C₃-H), 124.1 (d, $^2J_{CF}$ = 27.0 Hz, C_{7a}), 127.5 (CH_{Ar}), 127.9 (CH_{Ar}), 129.1 (CH_{Ar}), 129.3 (d, $^3J_{CF}$ = 2.5 Hz, C_{Ar}), 131.0 (CH_{Ar}), 131.7 (d, $^4J_{CF}$ = 1.0 Hz, CH_{Ar}), 133.2 (C_{Ar}-Cl), 138.4 (C_{Ar}), 141.2 (d, $^1J_{CF}$ = 242.5 Hz, C₇-F), 184.9 (d, $^4J_{CF}$ = 2.8 Hz, C=O).

^{19}F NMR (282 MHz, CDCl₃): δ -170.7 (d, J = 1.9 Hz).

HRMS (ESI): m/z calcd. for [C₁₉H₁₁ClFNOS + H⁺]: 356.0307, found: 356.0302

[6-(2-Chlorophenyl)-7-fluoropyrrolo[2,1-b][1,3]thiazol-5-yl](phenyl)methanone **3b**



Pyrrolo[2,1-b]thiazole **3b** was obtained from α -fluoronitroalkene **1b** (60.3 mg, 0.25 mmol) and thiazolium salt **2a** (2.5 equiv.) following the general procedure 1 (reaction time 8 h). Column chromatography (eluent: 7:1 PE/EtOAc) afforded **3b** (76 mg, 71%) as a yellow solid.

R_f = 0.37 (PE/EtOAc, 3:1) (UV), mp = 167-168°C (CHCl₃)


¹H NMR (300 MHz, CDCl₃): δ 6.83-6.94 (m, 2H, CH_{Ar}), 6.96 (d, J = 4.1 Hz, 1H, H2), 6.98-7.05 (m, 3H, CH_{Ar}), 7.11-7.17 (m, 1H, CH_{Ar}), 7.21 (dd, J = 8.0, 0.7 Hz, 1H, CH_{Ar}), 7.36-7.43 (m, 2H, CH_{Ar}), 8.81 (dd, J = 4.1, 1.8 Hz, 1H, H3).

¹³C NMR (75 MHz, CDCl₃): δ 113.3 (C2-H), 117.6 (C5), 120.8 (d, $^2J_{CF}$ = 10.5 Hz, C6), 123.9 (d, $^2J_{CF}$ = 28.2 Hz, C7a), 124.0 (C3-H), 126.0 (CH_{Ar}), 127.2 (CH_{Ar}), 128.6 (CH_{Ar}), 129.0 (CH_{Ar}), 129.1 (CH_{Ar}), 130.4 (d, $^3J_{CF}$ = 2.5 Hz, C_{Ar}), 130.7 (CH_{Ar}), 133.2 (CH_{Ar}), 134.2 (C_{Ar}-Cl), 138.6 (C_{Ar}), 141.5 (d, $^1J_{CF}$ = 243.2 Hz, C7-F), 185.0 (d, $^4J_{CF}$ = 2.8 Hz, C=O).

¹⁹F NMR (282 MHz, CDCl₃): δ -166.1 (d, J = 1.8 Hz).

HRMS (ESI): m/z calcd. for [C₁₉H₁₁ClFNOS + H⁺]: 356.0307, found: 356.0304.

[7-Fluoro-6-(4-methoxyphenyl)pyrrolo[2,1-b][1,3]thiazol-5-yl](phenyl)methanone **3c**



Pyrrolo[2,1-b]thiazole **3c** was obtained from α -fluoronitroalkene **1c** (39.4 mg, 0.2 mmol) and thiazolium salt **2a** (2.5 equiv.) following the general procedure 1 (reaction time 2 days). Column chromatography (eluent: 7:1 to 3:1 PE/EtOAc) afforded **3c** (47.5 mg, 53%) as a yellow solid.

R_f = 0.34 (PE/EtOAc, 3:1) (UV), mp = 126-129°C (CHCl₃)


¹H NMR (300 MHz, CDCl₃, COSY): δ 3.71 (s, 3H, OMe), 6.55-6.61 (m, 2H, CH_{Ar}), 6.90 (d, J = 4.1 Hz, 1H, H2), 6.93-7.07 (m, 4H, CH_{Ar}), 7.16-7.22 (m, 1H, CH_{Ar}), 7.36-7.42 (m, 2H, CH_{Ar}), 8.77 (dd, J = 4.1, 1.9 Hz, 1H, H3).

¹³C NMR (75 MHz, CDCl₃, DEPT-135, HSQC, HMBC): δ 55.2 (OMe), 112.5 (C2-H), 113.3 (CH_{Ar}), 117.3 (C5), 123.1 (d, $^3J_{CF}$ = 2.5 Hz, C_{Ar}), 124.0 (C3-H), 124.0 (d, $^2J_{CF}$ = 9.1 Hz, C6), 124.1 (d, $^2J_{CF}$ = 28.3 Hz, C7a), 127.4 (CH_{Ar}), 129.2 (CH_{Ar}), 130.7 (CH_{Ar}), 131.7 (d, $^4J_{CF}$ = 0.9 Hz, CH_{Ar}), 138.6 (C_{Ar}), 141.4 (d, $^1J_{CF}$ = 241.0 Hz, C7-F), 158.7 (C_{Ar}-OMe), 185.1 (d, $^4J_{CF}$ = 2.8 Hz, C=O).

^{19}F NMR (282 MHz, CDCl_3): δ -171.1 (s).

HRMS (ESI): m/z calcd. for $[\text{C}_{20}\text{H}_{14}\text{FNO}_2\text{S} + \text{H}^+]$: 352.0802, found: 352.0803.

[7-Fluoro-6-(4-nitrophenyl)pyrrolo[2,1-*b*][1,3]thiazol-5-yl](phenyl)methanone **3d**



Pyrrolo[2,1-*b*]thiazole **3d** was obtained from α -fluoronitroalkene **1d** (42.4 mg, 0.2 mmol) and thiazolium salt **2a** (2.5 equiv.) following the general procedure 1 (reaction time 3 h). Column chromatography (eluent: 5:1 PE/EtOAc) afforded **3d** (26 mg, 34%) as a bright yellow solid.

R_f = 0.30 (PE/EtOAc, 3:1) (UV), mp = 163-164°C (CHCl_3)


^1H NMR (300 MHz, CDCl_3 , COSY): δ 7.01 (d, J = 4.2 Hz, 1H, H2), 7.04 (d, J = 7.8 Hz, 2H, CH_{Ar}), 7.17-7.24 (m, 3H, CH_{Ar}), 7.33-7.39 (m, 2H, CH_{Ar}), 7.91 (d, J = 8.8 Hz, 2H, CH_{Ar}), 8.79 (dd, J = 4.2, 1.9 Hz, 1H, H3).

^{13}C NMR (75 MHz, CDCl_3): δ 114.1 (C2-H), 117.1 (C5), 121.3 (d, $^2J_{\text{CF}}$ = 8.7 Hz, C6), 122.7 (CH_{Ar}), 123.8 (C3-H), 124.2 (d, $^2J_{\text{CF}}$ = 28.0 Hz, C7a), 127.7 (CH_{Ar}), 129.1 (CH_{Ar}), 131.2 (d, $^4J_{\text{CF}}$ = 1.0 Hz, CH_{Ar}), 131.4 (CH_{Ar}), 137.8 (d, $^3J_{\text{CF}}$ = 2.6 Hz, C_{Ar}), 138.3 (C_{Ar}), 141.2 (d, $^1J_{\text{CF}}$ = 244.5 Hz, C7-F), 146.4 ($\text{C}_{\text{Ar}}\text{-NO}_2$), 184.7 (d, $^4J_{\text{CF}}$ = 2.7 Hz, C=O).

^{19}F NMR (282 MHz, CDCl_3): δ -170.1 (m).

HRMS (ESI): m/z calcd. for $[\text{C}_{19}\text{H}_{11}\text{FN}_2\text{O}_3\text{S} + \text{H}^+]$: 367.0547, found: 367.0550.

[6-(4-Chlorophenyl)-7-fluoropyrrolo[2,1-*b*][1,3]thiazol-5-yl](3-methoxyphenyl)methanone **3e**



Pyrrolo[2,1-*b*]thiazole **3e** was obtained from α -fluoronitroalkene **1a** (40.3 mg, 0.2 mmol) and thiazolium salt **2b** (2.5 equiv.) following the general procedure 1 (reaction time 3 h). Column chromatography (eluent: 5:1 PE/EtOAc) afforded **3e** (50 mg, 65%) as an amorphous yellow solid.

R_f = 0.31 (PE/EtOAc, 3:1) (UV)


^1H NMR (300 MHz, CDCl_3): δ 3.65 (s, 3H, OMe), 6.79 (m, 1H, CH_{Ar}), 6.88 (br s, 1H, CH_{Ar}), 6.94 (d, J = 4.1 Hz, 1H, H2), 6.96-7.07 (m, 6H, CH_{Ar}), 8.77 (dd, J = 4.1, 1.8 Hz, 1H, H3).

^{13}C NMR (75 MHz, CDCl_3): δ 55.2 (OMe), 113.2 (CH_{Ar}), 114.1 (C2-H), 117.2 (C5, overlapped signal), 117.2 (CH_{Ar}), 121.8 (CH_{Ar}), 122.7 (d, $^2J_{\text{CF}} = 9.0$ Hz, C6), 124.0 (C3-H), 124.2 (d, $^2J_{\text{CF}} = 28.4$ Hz, C7a), 127.8 (CH_{Ar}), 128.7 (CH_{Ar}), 129.4 (d, $^3J_{\text{CF}} = 2.5$ Hz, C_{Ar}), 131.5 (d, $^4J_{\text{CF}} = 0.9$ Hz, CH_{Ar}), 133.2 ($\text{C}_{\text{Ar}}\text{-Cl}$), 139.7 (C_{Ar}), 141.2 (d, $^1J_{\text{CF}} = 242.5$ Hz, C7-F), 158.9 ($\text{C}_{\text{Ar}}\text{-OMe}$), 184.6 (d, $^4J_{\text{CF}} = 2.8$ Hz, $\text{C}=\text{O}$).

^{19}F NMR (282 MHz, CDCl_3): δ -170.6 (s).

HRMS (ESI): m/z calcd. for $[\text{C}_{20}\text{H}_{13}\text{ClFNO}_2\text{S} + \text{H}^+]$: 386.0412, found: 386.0411.

[6-(4-Chlorophenyl)-7-fluoropyrrolo[2,1-*b*][1,3]thiazol-5-yl](3-nitrophenyl)methanone **3f**



Pyrrolo[2,1-*b*]thiazole **3f** was obtained from α -fluoronitroalkene **1a** (50.4 mg, 0.25 mmol) and thiazolium salt **2c** (2.5 equiv.) following the general procedure 1 (reaction time 1 h). Column chromatography (eluent: 5:1 PE/EtOAc) afforded **3f** (41 mg, 41%) as a bright yellow solid.

$R_f = 0.20$ (PE/EtOAc, 3:1) (UV) mp = 213-215°C (CHCl_3)


^1H NMR (300 MHz, CDCl_3): δ 6.94-7.02 (m, 4H, CH_{Ar}), 7.04 (d, $J = 4.1$ Hz, 1H, H2), 7.32 (dd, $J = 8.7, 7.7$ Hz, 1H, CH_{Ar}), 7.75 (d, $J = 7.7$ Hz, 1H, CH_{Ar}), 8.05-8.14 (m, 2H, CH_{Ar}), 8.82 (dd, $J = 4.1, 1.8$ Hz, 1H, H3).

^{13}C NMR (75 MHz, CDCl_3): δ 114.1 (C2-H), 116.7 (C5), 123.1 (d, $^2J_{\text{CF}} = 9.6$ Hz, C6), 124.0 (C3-H), 124.5 (CH_{Ar}), 125.1 (CH_{Ar}), 125.9 (d, $^2J_{\text{CF}} = 28.0$ Hz, C7a), 128.1 (CH_{Ar}), 128.6 (d, $^3J_{\text{CF}} = 2.3$ Hz, C_{Ar}), 128.9 (CH_{Ar}), 131.8 (br s, CH_{Ar}), 133.9 ($\text{C}_{\text{Ar}}\text{-Cl}$), 134.4 (CH_{Ar}), 139.9 (C_{Ar}), 141.4 (d, $^1J_{\text{CF}} = 243.8$ Hz, C7-F), 147.0 ($\text{C}_{\text{Ar}}\text{-NO}_2$), 181.5 (d, $^4J_{\text{CF}} = 3.0$ Hz, $\text{C}=\text{O}$).

^{19}F NMR (282 MHz, CDCl_3): δ -169.5 (s).

HRMS (ESI): m/z calcd. for $[\text{C}_{19}\text{H}_{10}\text{ClFN}_2\text{O}_3\text{S} + \text{H}^+]$: 401.0157, found: 401.0149.

Ethyl 6-(4-chlorophenyl)-7-fluoropyrrolo[2,1-*b*][1,3]thiazole-5-carboxylate **3g**



Pyrrolo[2,1-*b*]thiazole **3g** was obtained from α -fluoronitroalkene **1a** (40.3 mg, 0.2 mmol) and thiazolium salt **2d** (3.0 equiv.) following the general procedure 1 (reaction time 2 days). Column chromatography (eluent: 19:1 to 9:1 PE/EtOAc) afforded **3g** (36 mg, 57%) as a white solid.

$R_f = 0.47$ (PE/EtOAc, 3:1) (UV), mp = 102-103°C (CHCl_3)


^1H NMR (300 MHz, CDCl_3): δ 1.18 (t, $J = 7.1$ Hz, 3H, CH_3), 4.22 (q, $J = 7.1$ Hz, 2H, CH_2), 6.84 (d, $J = 4.2$ Hz, 1H, H2), 7.36-7.45 (m, 4H, CH_{Ar}), 8.43 (dd, $J = 4.2, 1.9$ Hz, 1H, H3).

^{13}C NMR (75 MHz, CDCl_3): δ 14.1 (CH_3), 60.1 (CH_2), 108.0 (d, $^3J_{\text{CF}} = 1.5$ Hz, C5), 112.3 (C2-H), 121.1 (d, $^2J_{\text{CF}} = 28.1$ Hz, C7a), 121.8 (d, $^2J_{\text{CF}} = 10.0$ Hz, C6), 123.3 (C3-H), 127.8 (CH_{Ar}), 129.4 (d, $^3J_{\text{CF}} = 2.4$ Hz, C_{Ar}), 131.9 (d, $^4J_{\text{CF}} = 1.0$ Hz, CH_{Ar}), 133.6 ($\text{C}_{\text{Ar}}\text{-Cl}$), 141.2 (d, $^1J_{\text{CF}} = 240.3$ Hz, C7-F), 160.7 (d, $^4J_{\text{CF}} = 2.7$ Hz, CO_2Et).

^{19}F NMR (282 MHz, CDCl_3): δ -171.1 (br s).

HRMS (ESI): m/z calcd. for $[\text{C}_{15}\text{H}_{11}\text{ClFNO}_2\text{S} + \text{Na}^+]$: 346.0075, found: 346.0069.

Benzyl 6-(4-chlorophenyl)-7-fluoropyrrolo[2,1-b][1,3]thiazole-5-carboxylate **3h**



Pyrrolo[2,1-b]thiazole **3h** was obtained from α -fluoronitroalkene **1a** (30.3 mg, 0.15 mmol) and thiazolium salt **2e** (3.5 equiv.) following the general procedure 1 (reaction time 3 days). Column chromatography (eluent: 19:1 to 9:1 PE/EtOAc) afforded **3h** (28.5 mg, 50%) as a white solid.

$R_f = 0.65$ (PE/EtOAc, 3:1) (UV), mp = 101-103°C (CHCl_3)


^1H NMR (300 MHz, CDCl_3): δ 5.18 (s, 2H, CH_2), 6.84 (d, $J = 4.2$ Hz, 1H, H2), 7.08 (dd, $J = 6.5, 2.9$ Hz, 2H, CH_{Ar}), 7.26-7.32 (m, 5H, CH_{Ar}), 7.36 (d, $J = 8.3$ Hz, 2H, CH_{Ar}), 8.44 (dd, $J = 4.2, 1.9$ Hz, 1H, H3).

^{13}C NMR (75 MHz, CDCl_3): δ 65.9 (CH_2), 107.8 (d, $^3J_{\text{CF}} = 1.7$ Hz, C5), 112.5 (C2-H), 121.6 (d, $^2J_{\text{CF}} = 28.1$ Hz, C7a), 122.1 (d, $^2J_{\text{CF}} = 10.6$ Hz, C6), 123.3 (C3-H), 127.9 (CH_{Ar}), 128.0 (CH_{Ar}), 128.1 (CH_{Ar}), 128.4 (CH_{Ar}), 129.3 (d, $^3J_{\text{CF}} = 2.2$ Hz, C_{Ar}), 131.9 (d, $^4J_{\text{CF}} = 0.9$ Hz, CH_{Ar}), 133.7 ($\text{C}_{\text{Ar}}\text{-Cl}$), 135.5 (C_{Ar}), 141.2 (d, $^1J_{\text{CF}} = 240.4$ Hz, C7-F), 160.5 (d, $^4J_{\text{CF}} = 2.9$ Hz, CO_2Et).

^{19}F NMR (282 MHz, CDCl_3): δ -171.4 (br s).

HRMS (ESI): m/z calcd. for $[\text{C}_{20}\text{H}_{13}\text{ClFNO}_2\text{S} + \text{H}^+]$: 386.0412, found: 386.0418.

1-[6-(4-Chlorophenyl)-7-fluoropyrrolo[2,1-b][1,3]thiazol-5-yl]ethan-1-one **3i**



Pyrrolo[2,1-b]thiazole **3i** was obtained from α -fluoronitroalkene **1a** (40.3 mg, 0.2 mmol) and thiazolium salt **2f** (3.0 equiv.) following the general procedure 1 (reaction time 48 h). Column

chromatography (eluent: 19:1 to 9:1 PE/EtOAc) afforded **3i** (26.5 mg, 44%) as a colorless oil, which solidifies upon storage in a refrigerator.

$R_f = 0.35$ (PE/EtOAc, 3:1) (UV)


$^1\text{H NMR}$ (300 MHz, CDCl_3): δ 1.99 (s, 3H, Me), 6.89 (d, $J = 4.1$ Hz, 1H, H2), 7.36-7.39 (m, 2H, CH_{Ar}), 7.45-7.48 (m, 2H, CH_{Ar}), 8.82 (dd, $J = 4.1, 1.8$ Hz, 1H, H3).

$^{13}\text{C NMR}$ (75 MHz, CDCl_3): δ 28.3 (Me), 112.9 (C2-H), 118.3 (C5), 122.0 (d, $^2J_{\text{CF}} = 10.3$ Hz, C6), 123.3 (d, $^2J_{\text{CF}} = 28.1$ Hz, C7a), 124.3 (C3-H), 128.8 (CH_{Ar}), 129.8 (d, $^3J_{\text{CF}} = 1.9$ Hz, C_{Ar}), 131.8 (br s, CH_{Ar}), 134.7 ($\text{C}_{\text{Ar}}\text{-Cl}$), 141.5 (d, $^1J_{\text{CF}} = 241.0$ Hz, C7-F), 186.2 (d, $^4J_{\text{CF}} = 2.8$ Hz, C=O).

$^{19}\text{F NMR}$ (282 MHz, CDCl_3): δ -171.0 (d, $J = 1.8$ Hz).

HRMS (ESI): m/z calcd. for $[\text{C}_{14}\text{H}_9\text{ClFNOS} + \text{H}^+]$: 293.0072, found: 293.0068.

Ethyl 5-benzoyl-6-(4-chlorophenyl)pyrrolo[2,1-*b*][1,3]thiazole-7-carboxylate **4a**



Pyrrolo[2,1-*b*]thiazole **4a** was obtained from nitroalkene **1e** (37 mg, 0.145 mmol) and thiazolium salt **2a** (2.5 equiv.) following the general procedure 1 (reaction time 10 h). Column chromatography (eluent: 5:1 PE/EtOAc) afforded **3k** (39 mg, 66%) as a slightly yellow solid.


$R_f = 0.33$ (PE/EtOAc, 3:1) (UV), mp = 158-161°C (CHCl_3)

$^1\text{H NMR}$ (300 MHz, CDCl_3): δ 1.25 (t, $J = 7.1$ Hz, 3H, CH_3), 4.24 (q, $J = 7.1$ Hz, 2H, CH_2), 6.92-6.98 (m, 2H, CH_{Ar}), 6.99-7.07 (m, 4H, CH_{Ar}), 7.13 (d, $J = 4.2$ Hz, 1H, H2), 7.20-7.32 (m, 3H, CH_{Ar}), 8.74 (d, $J = 4.2$ Hz, 1H, H3).

$^{13}\text{C NMR}$ (75 MHz, CDCl_3): δ 14.3 (CH_3), 60.3 (CH_2), 105.3 (C7), 115.4 (C2-H), 123.9 (C_q), 124.3 (C3-H), 127.0 (CH_{Ar}), 127.5 (CH_{Ar}), 128.8 (CH_{Ar}), 130.9 (CH_{Ar}), 131.4 (C_q), 132.5 (CH_{Ar}), 133.5 (C_q), 138.0 (C_q), 138.1 (C_q), 144.7 (C_q), 162.9 (CO_2Et), 186.8 (COPh).

HRMS (ESI): m/z calcd. for $[\text{C}_{22}\text{H}_{16}\text{ClNO}_3\text{S} + \text{H}^+]$: 410.0612, found: 410.0604.

Ethyl 5-benzoyl-6-(2-bromophenyl)pyrrolo[2,1-*b*][1,3]thiazole-7-carboxylate **4b**



Pyrrolo[2,1-b]thiazole **4b** was obtained from α -fluoronitroalkene **1f** (60 mg, 0.2 mmol) and thiazolium salt **2a** (2.5 equiv.) following the general procedure 1 (reaction time 5 h). Column chromatography (eluent: 5:1 PE/EtOAc) afforded **4b** (72 mg, 79%) as a slightly yellow solid.


$R_f = 0.35$ (PE/EtOAc, 3:1) (UV), mp = 123-126°C (CHCl₃)

¹H NMR (300 MHz, CDCl₃): δ 1.13 (t, $J = 7.1$ Hz, 3H, CH₃), 4.06-4.28 (m, 2H, CH₂), 6.89-6.91 (m, 3H, CH_{Ar}), 7.03 (t, $J = 7.5$ Hz, 1H), 7.14 (d, $J = 4.2$ Hz, 1H, H₂), 7.12-7.18 (m, 1H, CH_{Ar}), 7.32-7.36 (m, 1H, CH_{Ar}), 7.40-7.44 (m, 2H, CH_{Ar}), 8.77 (d, $J = 4.2$ Hz, 1H, H₃).

¹³C NMR (75 MHz, CDCl₃): δ 14.0 (CH₃), 60.2 (CH₂), 106.3 (C₇), 115.3 (C₂-H), 123.7 (C_q), 124.4 (C₃-H), 125.1 (C_{Ar}-Br), 126.0 (CH_{Ar}), 127.2 (CH_{Ar}), 128.2 (CH_{Ar}), 128.8 (CH_{Ar}), 130.8 (CH_{Ar}), 131.7 (CH_{Ar}), 132.4 (CH_{Ar}), 134.9 (C_q), 137.1 (C_q), 138.5 (C_q), 144.3 (C_q), 162.9 (CO₂Et), 186.6 (COPh).

HRMS (ESI): m/z calcd. for [C₂₂H₁₆BrNO₃S + H⁺]: 454.0107, found: 454.0098.

Ethyl 6-(4-chlorophenyl)-5-(3-methoxybenzoyl)pyrrolo[2,1-b][1,3]thiazole-7-carboxylate **4c**



Pyrrolo[2,1-b]thiazole **4c** was obtained from α -fluoronitroalkene **1e** (35 mg, 0.137 mmol) and thiazolium salt **2b** (2.5 equiv.) following the general procedure 1 (reaction time 4 h). Column chromatography (eluent: 4:1 PE/EtOAc) afforded **4c** (41 mg, 68%) as an amorphous slightly yellow solid.


$R_f = 0.26$ (PE/EtOAc, 3:1) (UV).

¹H NMR (300 MHz, CDCl₃): δ 1.25 (t, $J = 7.1$ Hz, 3H, CH₃), 3.69 (s, 3H, OMe), 4.23 (q, $J = 7.1$ Hz, 2H, CH₂), 6.74-6.80 (m, 1H, CH_{Ar}), 6.89 (dt, $J = 7.5, 1.2$ Hz, 1H, CH_{Ar}), 6.93-7.06 (m, 5H, CH_{Ar}), 7.12 (d, $J = 4.2$ Hz, 1H, H₂), 8.73 (d, $J = 4.2$ Hz, 1H, H₃).

¹³C NMR (75 MHz, CDCl₃): δ 14.2 (CH₃), 55.2 (OMe), 60.3 (CH₂), 105.3 (C₇), 114.0 (CH_{Ar}), 115.4 (C₂-H), 116.7 (CH_{Ar}), 121.3 (CH_{Ar}), 123.8 (C_q), 124.3 (C₃-H), 127.0 (CH_{Ar}), 128.8 (CH_{Ar}), 131.5 (C_q), 132.2 (CH_{Ar}), 133.4 (C_q), 138.1 (C_q), 139.5 (C_q), 144.7 (C_q), 158.6 (C_{Ar}-OMe), 162.9 (CO₂Et), 186.4 (COPh).

HRMS (ESI): m/z calcd. for [C₂₃H₁₈ClNO₄S + H⁺]: 410.0612, found: 410.0604.

Ethyl 6-(4-chlorophenyl)-5-(3-nitrobenzoyl)pyrrolo[2,1-b][1,3]thiazole-7-carboxylate **4d**



Pyrrolo[2,1-b]thiazole **4d** was obtained from α -fluoronitroalkene **1e** (44 mg, 0.172 mmol) and thiazolium salt **2c** (2.5 equiv.) following the general procedure 1 (reaction time 2 h). Column chromatography (eluent: 4:1 PE/EtOAc) afforded **4d** (36.5 mg, 51%) as a dark yellow solid.


R_f = 0.19 (PE/EtOAc, 3:1) (UV), mp = 172-175°C (CHCl₃)

¹H NMR (300 MHz, CDCl₃): δ 1.23 (t, J = 7.1 Hz, 3H, CH₃), 4.23 (q, J = 7.1 Hz, 2H, CH₂), 6.94 (d, J = 8.4 Hz, 2H, CH_{Ar}), 7.00-7.06 (m, 2H, CH_{Ar}), 7.20 (d, J = 4.2 Hz, 1H, H₂), 7.32 (t, J = 7.9 Hz, 1H, CH_{Ar}), 7.70 (app dt, J = 7.7, 1.3 Hz, 1H, CH_{Ar}), 7.99 (t, J = 1.8 Hz, 1H, CH_{Ar}), 8.09 (ddd, J = 8.2, 2.3, 1.1 Hz, 1H, CH_{Ar}), 8.78 (d, J = 4.2 Hz, 1H, H₃).

¹³C NMR (75 MHz, CDCl₃): δ 14.2 (CH₃), 60.5 (CH₂), 106.1 (C7), 116.1 (C2-H), 123.3 (C_q), 124.1 (CH), 124.3 (CH), 125.0 (CH), 127.2 (CH_{Ar}), 128.9 (CH_{Ar}), 131.1 (C_q), 132.4 (CH_{Ar}), 133.9 (C_q), 134.0 (CH_{Ar}), 138.7 (C_q), 139.7 (C_q), 145.5 (C_q), 146.9 (C_{Ar}-NO₂), 162.6 (CO₂Et), 183.5 (COPh).

HRMS (ESI): m/z calcd. for [C₂₂H₁₅ClN₂O₅S + H⁺]: 455.0463, found: 455.0454.

Diethyl 6-(4-chlorophenyl)pyrrolo[2,1-b][1,3]thiazole-5,7-dicarboxylate **4e**



Pyrrolo[2,1-b]thiazole **4e** was obtained from nitroalkene **1e** (51.6 mg, 0.2 mmol) and thiazolium salt **2d** (3.0 equiv.) following the general procedure 1 (reaction time 2 days). Column chromatography (eluent: 19:1 to 5:1 PE/EtOAc) afforded **4e** (37.5 mg, 47%) as a white solid.

R_f = 0.38 (PE/EtOAc, 3:1) (UV), mp = 114-115°C (CHCl₃)

¹H NMR (300 MHz, CDCl₃): δ 1.05 (t, J = 7.1 Hz, 3H, CH₃), 1.20 (t, J = 7.1 Hz, 3H, CH₃), 4.13 (q, J = 7.1 Hz, 2H, CH₂), 4.19 (q, J = 7.1 Hz, 2H, CH₂), 7.05 (d, J = 4.2 Hz, 1H, H₂), 7.27-7.38 (m, 4H, CH_{Ar}), 8.48 (d, J = 4.2 Hz, 1H, H₃).


¹³C NMR (75 MHz, CDCl₃): δ 13.8 (CH₃), 14.2 (CH₃), 60.1 (CH₂), 60.3 (CH₂), 105.7 (C7), 114.9 (C2-H), 115.0 (C_q), 123.6 (C3-H), 127.1 (CH_{Ar}), 131.4 (CH_{Ar}), 132.7 (C_q), 133.3 (C_q), 137.0 (C_q), 142.6 (C_q), 160.7 (CO₂Et), 163.0 (CO₂Et).

HRMS (ESI): m/z calcd. for [C₁₈H₁₆ClNO₄S + H⁺]: 378.0561, found: 378.0560.

General procedure 2 for the synthesis of 7-unsubstituted pyrrolo[2,1-b]thiazoles 5

To the solution of thiazolium salt **2** (0.5 mmol, 2.5 equiv.) in dry MeCN (1 ml) powdered 4Å molecular sieves (100 mg) and 2,6-lutidine (107 mg, 1 mmol, 5 equiv.) were added, followed by addition of nitroalkene **1** (0.2 mmol, 1.0 equiv.) and Cu(OCOCF₃)₂·H₂O (92 mg, 0.3 mmol, 1.5 equiv.) The mixture was stirred at r. t. for 5-24 hours. After the reaction was complete (TLC monitoring), it was evaporated after addition of silica gel. Crude product was purified by column chromatography using PE/EtOAc as an eluent to give pyrrolo[2,1-b]thiazoles **5**.

[6-(4-Chlorophenyl)pyrrolo[2,1-b][1,3]thiazol-5-yl](phenyl)methanone 5a



Pyrrolo[2,1-b]thiazole **5a** was obtained from nitroalkene **1g** (37 mg, 0.2 mmol) and thiazolium salt **2a** (2.5 equiv.) following the general procedure 2 (reaction time 5 h). Column chromatography (eluent: 15:1 to 5:1 PE/EtOAc) afforded **5a** (32 mg, 53%) as a slightly yellow solid.


R_f = 0.41 (PE/EtOAc, 3:1) (UV), mp = 141-142°C (CHCl₃)

¹H NMR (300 MHz, CDCl₃, COSY): δ 6.42 (s, 1H, H7), 6.93-6.98 (m, 5H, CH_{Ar}, H2), 7.02-7.08 (m, 2H, CH_{Ar}), 7.20-7.27 (m, 1H, CH_{Ar}), 7.37-7.41 (m, 2H, CH_{Ar}), 8.75 (d, *J* = 4.2 Hz, 1H, H3).

¹³C NMR (75 MHz, CDCl₃, HSQC, HMBC): δ 101.7 (C7-H), 113.1 (C2-H), 121.4 (C6), 124.0 (C3-H), 127.5 (CH_{Ar}), 127.7 (CH_{Ar}), 129.2 (CH_{Ar}), 130.8 (CH_{Ar}), 130.9 (CH_{Ar}), 132.7 (C_{Ar}-Cl), 134.2 (C_{Ar}), 138.9 (C_q), 139.0 (C_q), 139.1 (C_q), 185.1 (C=O).

HRMS (ESI): *m/z* calcd. for [C₁₉H₁₂ClNOS + H⁺]: 338.0401, found: 338.0396.

Phenyl(6-phenylpyrrolo[2,1-b][1,3]thiazol-5-yl)methanone 5b



Pyrrolo[2,1-b]thiazole **5b** was obtained from nitroalkene **1h** (37 mg, 0.2 mmol) and thiazolium salt **2a** (2.5 equiv.) following the general procedure 2 (reaction time 5 h). Column chromatography (eluent: 15:1 to 7:1 PE/EtOAc) afforded **5b** (44 mg, 58%) as a slightly yellow solid.


$R_f = 0.46$ (PE/EtOAc, 3:1) (UV) mp = 106-109°C (CHCl₃)

¹H NMR (300 MHz, CDCl₃): δ 6.46 (s, 1H, H7), 6.93 (d, $J = 4.2$ Hz, 1H, H2), 6.98-7.07 (m, 7H, CH_{Ar}), 7.12-7.20 (m, 1H, CH_{Ar}), 7.38-7.44 (m, 2H, CH_{Ar}), 8.77 (d, $J = 4.2$ Hz, 1H, H3).

¹³C NMR (75 MHz, CDCl₃, HSQC, HMBC): δ 101.8 (C7-H), 112.8 (C2-H), 121.4 (C6), 124.0 (C3-H), 126.6 (CH_{Ar}), 127.3 (CH_{Ar}), 127.5 (CH_{Ar}), 129.3 (CH_{Ar}), 129.8 (CH_{Ar}), 130.6 (CH_{Ar}), 135.6 (C_{Ar}), 139.0 (C_q), 139.1 (C_q), 140.4 (C_q), 185.3 (C=O).

HRMS (ESI): m/z calcd. for [C₁₉H₁₃NOS + H⁺]: 304.0791, found: 304.0802.

[6-(2-Bromophenyl)pyrrolo[2,1-*b*][1,3]thiazol-5-yl](phenyl)methanone **5c**



Pyrrolo[2,1-*b*]thiazole **5c** was obtained from nitroalkene **1j** (45.6 mg, 0.2 mmol) and thiazolium salt **2b** (2.5 equiv.) following the general procedure 2 (reaction time 6 h). Column chromatography (eluent: 15:1 to 7:1 PE/EtOAc) afforded **5c** (49 mg, 64%) as a slightly yellow oil, which solidifies upon storage in a refrigerator.


$R_f = 0.38$ (PE/EtOAc, 3:1) (UV)

¹H NMR (300 MHz, CDCl₃): δ 6.44 (s, 1H, H7), 6.86-7.04 (m, 6H, CH_{Ar}), 7.10-7.16 (m, 1H, CH_{Ar}), 7.34 (dd, $J = 6.9, 1.7$ Hz, CH_{Ar}), 7.42 (d, $J = 7.3$ Hz, 2H), 8.79 (d, $J = 4.1$ Hz, 1H, H3).

¹³C NMR (75 MHz, CDCl₃): δ 103.0 (C7-H), 113.2 (C2-H), 122.0 (C6), 123.8 (C_{Ar}-Br), 124.0 (C3-H), 126.3 (CH_{Ar}), 127.1 (CH_{Ar}), 128.5 (CH_{Ar}), 128.7 (CH_{Ar}), 130.4 (CH_{Ar}), 132.3 (CH_{Ar}), 132.8 (CH_{Ar}), 136.7 (C_{Ar}), 137.9 (C_q), 138.9 (C_q), 139.0 (C_q), 185.0 (C=O).

HRMS (ESI): m/z calcd. for [C₁₉H₁₂BrNOS + H⁺]: 381.9896, found: 381.9894.

[6-(4-Methoxyphenyl)pyrrolo[2,1-*b*][1,3]thiazol-5-yl](phenyl)methanone **5d**



Pyrrolo[2,1-*b*]thiazole **5d** was obtained from nitroalkene **1i** (35 mg, 0.2 mmol) and thiazolium salt **2a** (3.0 equiv.) following the general procedure 2 (reaction time 24 h). Column chromatography (eluent: 5:1 PE/EtOAc) afforded **5d** (31 mg, 47%) as an amorphous yellow solid.


$R_f = 0.34$ (PE/EtOAc, 3:1) (UV)

^1H NMR (300 MHz, CDCl_3): δ 3.70 (s, 3H, OMe), 6.41 (s, 1H, H7), 6.55 (d, $J = 8.8$ Hz, 2H, CH_{Ar}), 6.91 (d, $J = 4.2$ Hz, 1H, H2), 6.96 (d, $J = 8.8$ Hz, 2H, CH_{Ar}), 7.03 (t, $J = 7.6$ Hz, 2H), 7.15-7.21 (m, 1H, CH_{Ar}), 7.38-7.43 (m, 2H, CH_{Ar}), 8.75 (d, $J = 4.2$ Hz, 1H, H3).

^{13}C NMR (75 MHz, CDCl_3): δ 55.2 (OMe), 101.7 (C7-H), 112.5 (C2-H), 113.1 (CH_{Ar}), 121.4 (C6), 124.0 (C3-H), 127.3 (CH_{Ar}), 128.1 (C_{Ar}), 129.3 (CH_{Ar}), 130.5 (CH_{Ar}), 130.9 (CH_{Ar}), 139.0 (C_q), 139.1 (C_q), 140.2 (C_q), 158.5 ($\text{C}_{\text{Ar}}\text{-OMe}$), 185.2 (C=O).

HRMS (ESI): m/z calcd. for $[\text{C}_{20}\text{H}_{15}\text{NO}_2\text{S} + \text{H}^+]$: 334.0896, found: 334.0900.

[6-(5-Bromothiophen-2-yl)pyrrolo[2,1-*b*][1,3]thiazol-5-yl](phenyl)methanone **5e**



Pyrrolo[2,1-*b*]thiazole **5e** was obtained from nitroalkene **1k** (46.8 mg, 0.2 mmol) and thiazolium salt **2a** (3.0 equiv.) following the general procedure 2 (reaction time 24h). Column chromatography (eluent: 9:1 PE/EtOAc) afforded **5e** (43 mg, 56%) as a slightly yellow solid.


$R_f = 0.44$ (PE/EtOAc, 3:1) (UV), mp = 119-123°C (CHCl_3)

^1H NMR (300 MHz, CDCl_3 , COSY): δ 6.21 (d, $J = 3.8$ Hz, 1H, thiophene), 6.44 (s, 1H, H7), 6.57 (d, $J = 3.8$ Hz, 1H, thiophene), 6.95 (d, $J = 4.2$ Hz, 1H, H2), 7.19 (t, $J = 7.6$ Hz, 2H, CH_{Ar}), 7.30-7.37 (m, 1H, CH_{Ar}), 7.50-7.55 (m, 2H, CH_{Ar}), 8.68 (d, $J = 4.2$ Hz, 1H, H3).

^{13}C NMR (75 MHz, CDCl_3 , HSQC): δ 102.3 (C7-H), 112.1 (C(thiophene)-Br), 113.5 (C2-H), 121.5 (C6), 123.8 (C3-H), 127.8 (CH_{Ph}), 128.2 (CH(thiophene)), 128.9 (CH_{Ph}), 129.5 (CH(thiophene)), 130.6 (C_q (thiophene)), 131.1 (CH_{Ph}), 138.5 (C_q), 139.0 (C_q), 139.1 (C_q), 185.0 (C=O).

HRMS (ESI): m/z calcd. for $[\text{C}_{17}\text{H}_{10}\text{BrNOS}_2 + \text{H}^+]$: 387.9460, found: 387.9468.

Phenyl[6-(2-phenylethyl)pyrrolo[2,1-*b*][1,3]thiazol-5-yl]methanone **5f**



Pyrrolo[2,1-*b*]thiazole **5f** was obtained from α -fluoronitroalkene **1l** (35.4 mg, 0.2 mmol) and thiazolium salt **2a** (2.5 equiv.) following the general procedure 2 (reaction time 24 h). Column

chromatography (eluent: 9:1 PE/EtOAc) afforded **5f** (30.5 mg, 45%) as a slightly yellow oil, which solidifies upon storage in a refrigerator.

$R_f = 0.34$ (PE/EtOAc, 3:1) (UV)

$^1\text{H NMR}$ (300 MHz, CDCl_3): δ 2.54-2.73 (m, 4H, 2* CH_2), 6.27 (s, 1H, H7), 6.82 (d, $J = 6.4$ Hz, 2H, CH_{Ar}), 6.85 (d, $J = 4.3$ Hz, 1H, H2), 7.09-7.21 (m, 3H, CH_{Ar}), 7.42-7.55 (m, 3H, CH_{Ar}), 7.61-7.66 (m, 2H, CH_{Ar}), 8.59 (d, $J = 4.2$ Hz, 1H, H3).


$^{13}\text{C NMR}$ (75 MHz, CDCl_3): δ 30.6 (CH_2), 37.9 (CH_2), 101.7 (C7-H), 112.1 (C2-H), 122.5 (C6), 124.1 (C3-H), 125.8 (CH_{Ar}), 128.0 (CH_{Ar}), 128.2 (CH_{Ar}), 128.4 (CH_{Ar}), 130.7 (CH_{Ar}), 139.6 (C_q), 140.1 (2* C_q), 141.1 (C_q), 141.2 (C_q), 184.9 (C=O).

HRMS (ESI): m/z calcd. for $[\text{C}_{21}\text{H}_{17}\text{NOS} + \text{H}^+]$: 332.1104, found: 332.1102.

General procedure 3 for the synthesis of pyrrolo[1,2-b]indazoles 7.

To the solution of indazolium salt **6** (0.25 mmol, 2.5 equiv.) in dry DMSO (0.5 ml) powdered 4Å molecular sieves (100 mg) and 2,6-lutidine (54 mg, 0.5 mmol, 5 equiv.) were added, followed by addition of nitroalkene **1** (0.1 mmol, 1.0 equiv.) and $\text{Cu}(\text{OCOCF}_3)_2 \cdot \text{H}_2\text{O}$ (62 mg, 0.2 mmol, 2.0 equiv.) The mixture was stirred at r. t. for 24 hours (for **7c** and **7f** – 3 days). After the reaction was complete (TLC monitoring), it was quenched with EtOAc/1% aqueous Na_2EDTA solution (20+20 ml). Aqueous layer was extracted by EtOAc (3*20 ml). Combined organic layer was dried over anhydrous Na_2SO_4 and evaporated after addition of silica gel. Crude product was purified by column chromatography using PE/EtOAc as an eluent to give pyrrolo[1,2-b]indazoles **7**.

[2-(4-Chlorophenyl)-1-fluoro-5-methyl-5H-pyrrolo[1,2-b]indazol-3-yl](phenyl)methanone **7a**



Pyrrolo[1,2-b]indazole **7a** was obtained from α -fluoronitroalkene **1a** (20 mg, 0.1 mmol) and indazolium salt **6a** (2.5 equiv.) following the general procedure 3. Column chromatography (eluent: 19:1 to 7:1 PE/EtOAc) afforded **7a** (28 mg, 70%) as a bright yellow solid.

$R_f = 0.53$ (PE/EtOAc, 3:1) (UV), mp = 178-179°C (CHCl_3)


$^1\text{H NMR}$ (300 MHz, CDCl_3): δ 3.75 (s, 3H, N-Me), 7.02 (s, 4H, CH_{Ar}), 7.10 (t, $J = 7.7$ Hz, 2H), 7.26-7.35 (m, 3H, CH_{Ar}), 7.44-7.50 (m, 1H, CH_{Ar}), 7.51-7.56 (m, 2H, CH_{Ar}), 7.84 (d, $J = 7.7$ Hz, 1H).

^{13}C NMR (75 MHz, CDCl_3): δ 41.8 (N-Me), 111.5 (CH), 115.6 (C3), 116.8 (d, $^3J_{\text{CF}} = 2.9$ Hz, C9a), 119.3 (d, $^2J_{\text{CF}} = 9.4$ Hz, C2), 120.4 (C9-H), 121.2 (d, $^2J_{\text{CF}} = 28.5$ Hz, C9b), 123.4 (CH), 127.6 (CH), 127.7 (CH_{Ar}), 127.8 (CH_{Ar}), 129.6 (CH_{Ar}), 129.7 (d, $^3J_{\text{CF}} = 2.3$ Hz, C_{Ar}), 131.6 (CH_{Ar}), 131.9 (d, $^4J_{\text{CF}} = 0.7$ Hz, CH_{Ar}), 132.8 ($\text{C}_{\text{Ar}}\text{-Cl}$), 137.5 (d, $^1J_{\text{CF}} = 242.8$ Hz, C1-F), 138.8 (C_{Ph}), 149.0 (C5a), 183.8 (d, $^4J_{\text{CF}} = 2.4$ Hz, C=O).

^{19}F NMR (282 MHz, CDCl_3): δ -172.4 (s).

HRMS (ESI): m/z calcd. for $[\text{C}_{24}\text{H}_{16}\text{ClFN}_2\text{O} + \text{H}^+]$: 403.1008, found: 403.0998.

[2-(2-Chlorophenyl)-1-fluoro-5-methyl-5H-pyrrolo[1,2-b]indazol-3-yl](phenyl)methanone
7b



Pyrrolo[1,2-b]indazole **7b** was obtained from α -fluoronitroalkene **1b** (20 mg, 0.1 mmol) and indazolium salt **6a** (2.5 equiv.) following the general procedure 3. Column chromatography (eluent: 19:1 to 7:1 PE/EtOAc) afforded **7b** (33 mg, 82%) as a bright yellow solid

$R_f = 0.40$ (PE/EtOAc, 3:1) (UV), mp = 176-177°C (CHCl_3)


^1H NMR (300 MHz, CDCl_3): δ 3.80 (s, 3H, N-Me), 6.85-6.92 (m, 1H, CH_{Ar}), 6.96-7.11 (m, 4H, CH_{Ar}), 7.15-7.22 (m, 2H, CH_{Ar}), 7.29-7.33 (m, 1H, CH_{Ar}), 7.35 (d, $J = 8.3$ Hz, 1H, CH_{Ar}), 7.48 (ddd, $J = 8.3, 7.3, 1.2$ Hz, 1H, CH_{Ar}), 7.53-7.56 (m, 2H, CH_{Ar}), 7.85 (d, $J = 7.7$ Hz, 1H, CH_{Ar}).

^{13}C NMR (75 MHz, CDCl_3): δ 41.3 (N-Me), 111.2 (CH), 115.7 (d, $^3J_{\text{CF}} = 0.9$ Hz, C3), 116.8 (d, $^3J_{\text{CF}} = 2.9$ Hz, C9a), 117.3 (d, $^2J_{\text{CF}} = 10.8$ Hz, C2), 120.4 (C9-H), 121.1 (d, $^2J_{\text{CF}} = 28.6$ Hz, C9b), 123.3 (CH), 125.8 (CH), 127.3 (CH), 127.6 (CH), 128.8 (CH), 128.9 (CH), 129.1 (CH), 130.8 (d, $^3J_{\text{CF}} = 2.3$ Hz, C_{Ar}), 131.3 (CH), 133.5 (CH), 134.5 ($\text{C}_{\text{Ar}}\text{-Cl}$), 137.8 (d, $^1J_{\text{CF}} = 243.5$ Hz, C1-F), 139.0 (C_{Ph}), 148.7 (C5a), 183.7 (d, $^4J_{\text{CF}} = 2.5$ Hz, C=O).

^{19}F NMR (282 MHz, CDCl_3): δ -167.9 (s).

HRMS (ESI): m/z calcd. for $[\text{C}_{24}\text{H}_{16}\text{ClFN}_2\text{O} + \text{H}^+]$: 403.1008, found: 403.1006.

[1-Fluoro-2-(4-methoxyphenyl)-5-methyl-5H-pyrrolo[1,2-b]indazol-3-yl](phenyl)methanone
7c



Pyrrolo[1,2-b]indazole **7c** was obtained from α -fluoronitroalkene **1c** (20 mg, 0.1 mmol) and indazolium salt **6a** (3.0 equiv.) following the general procedure 3 (reaction time 3 days). Column chromatography (eluent: 19:1 to 5:1 PE/EtOAc) afforded **7c** (26.5 mg, 67%) as a bright yellow solid.

$R_f = 0.29$ (PE/EtOAc, 3:1) (UV), mp = 173-176°C (CHCl₃)


¹H NMR (300 MHz, CDCl₃): δ 3.71 (s, 3H, OMe), 3.75 (s, 3H, N-Me), 6.60 (d, $J = 8.7$ Hz, 2H, CH_{Ar}), 7.01 (d, $J = 8.4$ Hz, 2H, CH_{Ar}), 7.08 (t, $J = 7.3$ Hz, 2H, CH_{Ar}), 7.20-7.35 (m, 3H, CH_{Ar}), 7.42-7.49 (m, 1H, CH_{Ar}), 7.54 (d, $J = 7.3$ Hz, 2H, CH_{Ar}), 7.83 (d, $J = 7.7$ Hz, 1H, CH_{Ar}).

¹³C NMR (75 MHz, CDCl₃): δ 41.9 (N-Me), 55.1 (OMe), 111.5 (CH), 113.2 (CH_{Ar}), 115.7 (C3), 117.1 (d, $^3J_{CF} = 3.0$ Hz, C9a), 120.3 (d, $^4J_{CF} = 0.7$ Hz, C9-H), 120.5 (d, $^2J_{CF} = 9.6$ Hz, C2), 121.2 (d, $^2J_{CF} = 28.8$ Hz, C9b), 123.3 (CH), 123.5 (d, $^3J_{CF} = 2.3$ Hz, C_{Ar}), 127.4 (CH), 127.5 (CH_{Ar}), 129.6 (CH_{Ar}), 131.3 (CH_{Ar}), 131.8 (br s, CH_{Ar}), 137.7 (d, $^1J_{CF} = 241.4$ Hz, C1-F), 138.9 (C_{Ph}), 149.2 (C5a), 158.4 (C_{Ar}-OMe), 184.0 (d, $^4J_{CF} = 2.4$ Hz, C=O).

¹⁹F NMR (282 MHz, CDCl₃): δ -172.4 (s).

HRMS (ESI): m/z calcd. for [C₂₅H₁₉FN₂O₃ + H⁺]: 399.1503, found: 399.1494.

Ethyl 2-(4-chlorophenyl)-1-fluoro-5-methyl-5H-pyrrolo[1,2-b]indazole-3-carboxylate 7d



Pyrrolo[1,2-b]indazole **7d** was obtained from α -fluoronitroalkene **1a** (20 mg, 0.1 mmol) and indazolium salt **6b** (3.0 equiv.) following the general procedure 3 (reaction time 3 days). Column chromatography (eluent: 19:1 to 7:1 PE/EtOAc) afforded **7b** (22 mg, 59%) as a white solid

$R_f = 0.50$ (PE/EtOAc, 3:1) (UV), mp = 108-110°C (CHCl₃)


¹H NMR (300 MHz, CDCl₃): δ 1.10 (t, $J = 7.1$ Hz, 3H, CH₃), 3.76 (s, 3H, N-Me), 4.18 (q, $J = 7.1$ Hz, 1H, CH₂), 7.26-7.33 (m, 2H, CH_{Ar}), 7.36-7.45 (m, 5H, CH_{Ar}), 7.76 (d, $J = 7.7$ Hz, 1H, CH_{Ar}).

^{13}C NMR (75 MHz, CDCl_3): δ 13.9 (CH_3), 43.6 (N-Me), 60.2 (CH_2), 107.6 (d, $^3J_{\text{CF}} = 1.3$ Hz, C3), 112.3 (CH), 117.8 (d, $^4J_{\text{CF}} = 2.9$ Hz, C9a), 119.1 (d, $^2J_{\text{CF}} = 9.9$ Hz, C2), 120.1 (d, $^4J_{\text{CF}} = 1.1$ Hz, C9-H), 120.6 (d, $^2J_{\text{CF}} = 28.1$ Hz, C9b), 123.7 (CH), 127.1 (CH), 127.7 (CH_{Ar}), 130.1 (d, $^3J_{\text{CF}} = 2.3$ Hz, C_{Ar}), 132.1 (d, $^4J_{\text{CF}} = 1.0$ Hz, CH_{Ar}), 133.2 ($\text{C}_{\text{Ar}}\text{-Cl}$), 137.6 (d, $^1J_{\text{CF}} = 241.4$ Hz, C1-F), 150.3 (C5a-NMe), 159.9 (d, $^4J_{\text{CF}} = 2.3$ Hz, CO_2Et).

^{19}F NMR (282 MHz, CDCl_3): δ -173.0 (s).

HRMS (ESI): m/z calcd. for $[\text{C}_{20}\text{H}_{16}\text{ClFN}_2\text{O}_2 + \text{H}^+]$: 371.0957, found: 371.0951.

Ethyl 3-benzoyl-2-(4-chlorophenyl)-5-methyl-5H-pyrrolo[1,2-b]indazole-1-carboxylate **7e**



Pyrrolo[1,2-b]indazole **7e** was obtained from α -fluoronitroalkene **1e** (25.5 mg, 0.1 mmol) and indazolium salt **6a** (2.5 equiv.) following the general procedure 3. Column chromatography (eluent: 19:1 to 5:1 PE/EtOAc) afforded **7e** (28.5 mg, 62%) as a slightly yellow solid.


$R_f = 0.39$ (PE/EtOAc, 3:1) (UV), mp = 189-191°C (CHCl_3)

^1H NMR (300 MHz, CDCl_3): δ 1.21 (t, $J = 7.1$ Hz, 3H, CH_3), 3.73 (s, 3H, N-Me), 4.26 (q, $J = 7.1$ Hz, 2H, CH_2), 6.97 (d, $J = 8.3$ Hz, 2H, CH_{Ar}), 7.04 (d, $J = 8.3$ Hz, 2H, CH_{Ar}), 7.11 (t, $J = 7.7$ Hz, 2H, CH_{Ar}), 7.27-7.42 (m, 3H, CH_{Ar}), 7.48-7.52 (m, 2H, CH_{Ar}), 7.53-7.60 (m, 1H, CH_{Ar}), 8.57 (d, $J = 7.9$ Hz, 1H, CH_{Ar}).

^{13}C NMR (75 MHz, CDCl_3): δ 14.3 (CH_3), 40.3 (N-Me), 59.9 (CH_2), 102.0 (C1), 110.6 (CH), 117.2 (C_q), 122.9 (CH), 123.9 (CH), 126.9 (CH_{Ar}), 127.7 (CH_{Ar}), 128.6 (CH), 128.7 (C_q), 129.4 (CH_{Ar}), 131.8 (CH_{Ar}), 132.5 (CH_{Ar}), 132.7 (C_q), 132.9 (C_q), 135.2 (C_q), 135.6 (C_q), 138.5 (C_{Ph}), 148.9 (C5a), 164.1 (CO_2Et), 185.6 (C=O).

HRMS (ESI): m/z calcd. for $[\text{C}_{27}\text{H}_{21}\text{ClN}_2\text{O}_3 + \text{H}^+]$: 457.1313, found: 457.1312.

[2-(4-Chlorophenyl)-5-methyl-5H-pyrrolo[1,2-b]indazol-3-yl](phenyl)methanone **7f**



Pyrrolo[1,2-b]indazole **7f** was obtained from nitroalkene **1g** (18.4 mg, 0.1 mmol) and indazolium salt **6a** (2.5 equiv.) following the general procedure 3 using MeCN as a solvent. Column

chromatography (eluent: 19:1 to 9:1 PE/EtOAc) afforded **7f** (13.5 mg, 35%) as a slightly yellow solid

$R_f = 0.43$ (PE/EtOAc, 3:1) (UV), mp = 168-170°C (CHCl₃)

¹H NMR (300 MHz, CDCl₃, COSY): δ 3.79 (s, 3H, N-Me), 6.50 (s, 1H, C1-H), 6.98-7.05 (m, 4H, CH_{Ar}), 7.13 (t, $J = 7.7$ Hz, 2H, CH_{Ar}), 7.27-7.34 (m, 2H, CH_{Ar}), 7.39 (d, $J = 8.3$ Hz, 1H, CH_{Ar}), 7.49 (ddd, $J = 8.3, 7.2, 1.2$ Hz, 1H, CH_{Ar}), 7.58 (dd, $J = 8.2, 1.2$ Hz, 2H, CH_{Ar}), 7.81 (d, $J = 7.7$ Hz, 1H, CH_{Ar}).

¹³C NMR (75 MHz, CDCl₃, HSQC): δ 41.5 (N-Me), 97.2 (C1-H), 111.7 (CH), 118.1 (C_q), 120.1 (C9-H), 123.0 (CH), 127.5 (CH), 127.59 (CH_{Ar}), 127.63 (CH_{Ar}), 129.7 (CH_{Ar}), 131.1 (CH_{Ar}), 131.5 (CH_{Ar}), 132.3 (C_{Ar}-Cl), 134.0 (C_q), 135.1 (C_q), 135.7 (C_q), 139.3 (C_{Ph}), 149.7 (C5a), 184.4 (C=O).

HRMS (ESI): m/z calcd. for [C₂₄H₁₇ClN₂O + H⁺]: 385.1102, found: 385.1092.


References

- s1 V. A. Motornov, V. M. Muzalevskiy, A. A. Tabolin, R. A. Novikov, Yu. V. Nelyubina, V. G. Nenajdenko, S. L. Ioffe, *J. Org. Chem.* 2017, **82**, 5274.
- s2 V. A. Motornov, A. A. Tabolin, Yu. V. Nelyubina, S. L. Ioffe, I. V. Smolyar, V. G. Nenajdenko, *Eur. J. Org. Chem.*, 2017, 6851.
- s3 J. Liu, L. Gong, E. Meggers, *Tetrahedron Lett.*, 2015, **56**, 4653.
- s4 A. A. Fadeeva, S. L. Ioffe, A. A. Tabolin, *Synthesis*, 2020, **52**, 2679.
- s5 Ji, X.; Tong, H.; Yuan, Y. *Synth. Commun.*, 2011, **47**, 372-379.
- s6 Kolarovic, A.; Kaslin, A.; Wennemers, H. *Org. Lett.*, 2014, **16**, 4236-4239.
- s7 A. J. Simpson, H. W. Lam, *Org. Lett.*, 2003, **15**, 2586-2589.
- s8 T. Ukai, R. Tanaka, T. Dokawa, *Yakugaki Zasshi*, 1943, **63**, 296. [*Chem. Abstr.* 1951, **45**, 5148].
- s9 M. T. Gandasegui, J. Alvarez-Builla, *Heterocycles*, 1990, **31**, 1801.

Copies of NMR spectra


3-(2-oxo-2-phenylethyl)-1,3-thiazol-3-ium bromide **2a**

^1H NMR




3-[2-(3-methoxyphenyl)-2-oxoethyl]-1,3-thiazol-3-ium bromide **2b**


^1H NMR



^{13}C NMR




DEPT-135 ^{13}C NMR




3-[2-(3-nitrophenyl)-2-oxoethyl]-1,3-thiazol-3-ium bromide **2c**


^1H NMR



^{13}C NMR




DEPT-135 ^{13}C NMR




3-(2-ethoxy-2-oxoethyl)-1,3-thiazol-3-ium bromide **2d**


^1H NMR



^{13}C NMR




DEPT-135 ^{13}C NMR




3-[2-(benzyloxy)-2-oxoethyl]-1,3-thiazol-3-ium bromide **2e**


^1H NMR



^{13}C NMR




DEPT-135 ^{13}C NMR




3-(2-oxopropyl)-1,3-thiazol-3-ium chloride **2f**


^1H NMR



^{13}C NMR




DEPT-135 ^{13}C NMR




1-methyl-2-(2-oxo-2-phenylethyl)-1*H*-indazol-2-ium bromide **6a**


¹H NMR



^{13}C NMR




DEPT-135 ^{13}C NMR




2-(2-ethoxy-2-oxoethyl)-1-methyl-1*H*-indazol-2-ium bromide **6b**


¹H NMR



^{13}C NMR




DEPT-135 ^{13}C NMR




[6-(4-chlorophenyl)-7-fluoropyrrolo[2,1-b][1,3]thiazol-5-yl](phenyl)methanone **3a**


^1H NMR



^{13}C NMR




^{19}F NMR




[6-(2-chlorophenyl)-7-fluoropyrrolo[2,1-*b*][1,3]thiazol-5-yl](phenyl)methanone **3b**


¹H NMR



^{13}C NMR




^{19}F NMR




[7-fluoro-6-(4-methoxyphenyl)pyrrolo[2,1-b][1,3]thiazol-5-yl](phenyl)methanone **3c**


¹H NMR




^{13}C NMR




DEPT-135 ^{13}C NMR




^1H - ^1H COSY NMR




^1H - ^{13}C HSQC NMR



^1H - ^{13}C HMBC NMR




^{19}F NMR




[7-fluoro-6-(4-nitrophenyl)pyrrolo[2,1-*b*][1,3]thiazol-5-yl](phenyl)methanone **3d**


¹H NMR




^{13}C NMR



^1H - ^1H COSY




^{19}F NMR




[6-(4-chlorophenyl)-7-fluoropyrrolo[2,1-*b*][1,3]thiazol-5-yl](3-methoxyphenyl)methanone **3e**


^1H NMR



^{13}C NMR




^{19}F NMR




[6-(4-chlorophenyl)-7-fluoropyrrolo[2,1-*b*][1,3]thiazol-5-yl](3-nitrophenyl)methanone **3f**


¹H NMR



^{13}C NMR




^{19}F NMR




ethyl 6-(4-chlorophenyl)-7-fluoropyrrolo[2,1-b][1,3]thiazole-5-carboxylate **3g**


^1H NMR



^{13}C NMR




^{19}F NMR




benzyl 6-(4-chlorophenyl)-7-fluoropyrrolo[2,1-*b*][1,3]thiazole-5-carboxylate **3h**


^1H NMR



^{13}C NMR




^{19}F NMR




1-[6-(4-chlorophenyl)-7-fluoropyrrolo[2,1-*b*][1,3]thiazol-5-yl]ethan-1-one **3i**


¹H NMR



^{13}C NMR




^{19}F NMR




ethyl 5-benzoyl-6-(4-chlorophenyl)pyrrolo[2,1-*b*][1,3]thiazole-7-carboxylate **4a**

^1H NMR




^{13}C NMR




ethyl 5-benzoyl-6-(2-bromophenyl)pyrrolo[2,1-*b*][1,3]thiazole-7-carboxylate **4b**

^1H NMR




^{13}C NMR




ethyl 6-(4-chlorophenyl)-5-(3-methoxybenzoyl)pyrrolo[2,1-*b*][1,3]thiazole-7-carboxylate **4c**

^1H NMR




^{13}C NMR




ethyl 6-(4-chlorophenyl)-5-(3-nitrobenzoyl)pyrrolo[2,1-b][1,3]thiazole-7-carboxylate **4d**

¹H NMR




^{13}C NMR




diethyl 6-(4-chlorophenyl)pyrrolo[2,1-*b*][1,3]thiazole-5,7-dicarboxylate **4e**

^1H NMR




^{13}C NMR




[6-(4-chlorophenyl)pyrrolo[2,1-*b*][1,3]thiazol-5-yl](phenyl)methanone **5a**


¹H NMR




^{13}C NMR




^1H - ^1H COSY NMR



^1H - ^{13}C HSQC NMR




^1H - ^{13}C HMBC NMR




phenyl(6-phenylpyrrolo[2,1-*b*][1,3]thiazol-5-yl)methanone **5b**


¹H NMR




^{13}C NMR



^1H - ^{13}C HSQC NMR




^1H - ^{13}C HMBC NMR




[6-(2-bromophenyl)pyrrolo[2,1-b][1,3]thiazol-5-yl](phenyl)methanone **5c**

^1H NMR




^{13}C NMR




[6-(4-methoxyphenyl)pyrrolo[2,1-*b*][1,3]thiazol-5-yl](phenyl)methanone **5d**

¹H NMR




^{13}C NMR




[6-(5-bromothiophen-2-yl)pyrrolo[2,1-*b*][1,3]thiazol-5-yl](phenyl)methanone **5e**


^1H NMR




^{13}C NMR



^1H - ^1H COSY NMR




^1H - ^{13}C HSQC NMR




phenyl[6-(2-phenylethyl)pyrrolo[2,1-*b*][1,3]thiazol-5-yl]methanone **5f**


^1H NMR



^{13}C NMR




^1H - ^{13}C HMBC NMR




[2-(4-chlorophenyl)-1-fluoro-5-methyl-5H-pyrrolo[1,2-b]indazol-3-yl](phenyl)methanone **7a**


¹H NMR



^{13}C NMR




^{19}F NMR




[2-(2-chlorophenyl)-1-fluoro-5-methyl-5H-pyrrolo[1,2-b]indazol-3-yl](phenyl)methanone **7b**


¹H NMR



^{13}C NMR




^{19}F NMR




[1-fluoro-2-(4-methoxyphenyl)-5-methyl-5H-pyrrolo[1,2-b]indazol-3-yl](phenyl)methanone **7c**


¹H NMR



^{13}C NMR




^{19}F NMR




ethyl 2-(4-chlorophenyl)-1-fluoro-5-methyl-5*H*-pyrrolo[1,2-*b*]indazole-3-carboxylate **7d**


¹H NMR



^{13}C NMR




^{19}F NMR




ethyl 3-benzoyl-2-(4-chlorophenyl)-5-methyl-5H-pyrrolo[1,2-b]indazole-1-carboxylate **7e**

^1H NMR




^{13}C NMR




[2-(4-chlorophenyl)-5-methyl-5H-pyrrolo[1,2-b]indazol-3-yl](phenyl)methanone **7f**


¹H NMR




^{13}C NMR




^1H - ^1H COSY NMR



^1H - ^{13}C HSQC NMR



^1H - ^{13}C HMBC NMR



^{19}F NMR of reaction mixture containing primary cycloadduct **8**

